Jacobio Pharmaceuticals Co.
Trial Pipeline
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
NCT06973564
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
NCT06386146
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT05490472
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
NCT05002270
A First in Human, Dose Escalation Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors
NCT03518554
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 33 |
What the Pipeline for Jacobio Pharmaceuticals Co. Shows
According to the ClinicalTrials.gov registry, Jacobio Pharmaceuticals Co. is linked to 33 US clinical trials across every stage of research activity. Of those, 31 studies are currently recruiting — about 94% of the sponsor's indexed portfolio — and 2 are already marked complete, representing roughly 6% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Jacobio Pharmaceuticals Co. reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 33 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Jacobio Pharmaceuticals Co. is Solid Tumors with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.